STOCK EXCHANGE RELEASE – OTHER INFORMATION DISCLOSED ACCORDING TO THE RULES OF THE EXCHANGE
Composition of the
The Board of Directors of
Annika Ekman Petteri Karttunen Minna Maasilta - Hilpi Rautelin
Seppo Salonen - Mikael Silvennoinen
The Committee prepares and presents a recommendation to the Board of Directors for the proposal to the Annual General Meeting concerning the composition of the Board.
The essentials of the charter of the Nomination Committee and a description of the appointment process of its members are provided at https://www.orion.fi/en/investors/corporate-governance/board-of-directors/nomination-committee/charter-of-the-nomination-committee/, a page in the Corporate Governance section of the Orion Group website.
President and CEO | SVP, Corporate Functions |
Contact person:
tel. +358 10 426 3054
Publisher:
Communications
Orionintie 1A, FI-02200 Espoo,
http://www.orion.fi/en
http://www.twitter.com/OrionCorpIR
Orion is a globally operating Finnish pharmaceutical company – a builder of well-being. We develop, manufacture and market human and veterinary pharmaceuticals and active pharmaceutical ingredients. Orion has an extensive portfolio of proprietary and generic medicines and self-care products. The core therapy areas of our pharmaceutical R&D are oncology and pain. Proprietary products developed by Orion are used to treat cancer, neurological diseases and respiratory diseases, among others. Orion's net sales in 2022 amounted to
© OMX, source